Product
Alectinib
Aliases
Alecensa, alectinib, Alectinib - Study, Alectinib - Usual (3 other aliases)
Name
ALECENSA
FDA Approved
Yes
29 clinical trials
1 organization
1 drug
73 indications
1 document
Indication
Lung CancerIndication
CancerIndication
Solid TumorsIndication
Bile Duct CancerIndication
Salivary CancerIndication
Bladder CancerIndication
ALK Fusion-positive Solid or CNS TumorsIndication
ALK-positive Non-small Cell Lung CancerIndication
NSCLCIndication
Non-Small-Cell Lung CarcinomaIndication
Anaplastic Large Cell LymphomaIndication
Non-small-cell Lung CarcinomaIndication
Cancer of Unknown Primary SiteIndication
Colorectal CancerIndication
MelanomaIndication
Pancreatic CancerIndication
SarcomaIndication
Ovarian CancerIndication
Brain NeoplasmsIndication
Thyroid CancerIndication
Neuroendocrine TumorsIndication
CholangiocarcinomaIndication
Salivary Gland NeoplasmsIndication
Head and Neck NeoplasmsIndication
PapillaryIndication
lymphomaIndication
Large CellIndication
AnaplasticIndication
Neoplasms by SiteIndication
Respiratory Tract NeoplasmsIndication
Thoracic NeoplasmsIndication
Respiratory Tract DiseasesIndication
cancerIndication
BronchogenicIndication
Bronchial NeoplasmsIndication
Intestinal NeoplasmsIndication
Gastrointestinal NeoplasmsIndication
Digestive System NeoplasmsIndication
Gastrointestinal DiseasesIndication
Colonic DiseasesIndication
Intestinal DiseasesIndication
Central Nervous SystemIndication
Non-small Cell Lung Cancer Stage IIIBIndication
ALK Gene MutationIndication
Non-Small Cell Lung Cancer Stage IVIndication
Breast CancerIndication
Gastrointestinal CancerIndication
GlioblastomaIndication
AdultIndication
Advanced CancerIndication
Solid TumorIndication
Haematological MalignancyIndication
Therapeutic Drug MonitoringIndication
Non-Small Cell LungIndication
lung cancerIndication
Anaplastic Lymphoma Kinase Gene MutationIndication
Breast CarcinomaIndication
Malignant NeoplasmIndication
Pancreatic CarcinomaIndication
Prostate CancerIndication
Advanced SarcomaIndication
Breast Cancer, Stage IVIndication
Soft Tissue SarcomaIndication
Recurrent Ovarian CarcinomaIndication
Stage III Ovarian Cancer AJCC v8Indication
Stage III Pancreatic CancerIndication
Stage IV Ovarian CancerIndication
EGFR gene mutationIndication
ROS1 Gene MutationIndication
MET Gene MutationIndication
Hepatocellular CarcinomaDrug
alectinibClinical trial
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2017-02-09
Clinical trial
Explore the Relationship Between Single Nucleotide Polymorphisms and Alectinib Response and Toxicity in Patients With Non-Small Cell Lung Cancer.Status: Not yet recruiting, Estimated PCD: 2024-11-18
Clinical trial
My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These AgentsStatus: Completed, Estimated PCD: 2023-05-24
Clinical trial
NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment AvailableStatus: Recruiting, Estimated PCD: 2026-06-07
Clinical trial
An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)Status: Recruiting, Estimated PCD: 2028-07-05
Clinical trial
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2018-05-31
Clinical trial
A Multicenter Non-Interventional Cohort Study to Evaluate the Real-World Clinical Management and Outcomes of Patients Diagnosed With ALK-Positive Advanced NSCLC Treated With Alectinib (ReAlec)Status: Active (not recruiting), Estimated PCD: 2027-05-10
Clinical trial
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform TrialStatus: Recruiting, Estimated PCD: 2032-09-25
Clinical trial
A Multicenter, International, Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive CancerStatus: Recruiting, Estimated PCD: 2024-06-12
Clinical trial
A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy.Status: Active (not recruiting), Estimated PCD: 2025-05-06
Clinical trial
A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2029-06-17
Clinical trial
Patient Profiles and Treatment Patterns Among ALK-positive NSCLC Patients Treated With AlectinibStatus: Completed, Estimated PCD: 2022-11-01
Clinical trial
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)Status: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
Treatment Registry of Alecensa in Korean Patients With Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung CancerStatus: Completed, Estimated PCD: 2021-05-28
Clinical trial
An Observational Parallel Group Phase 4 Study to Determine Progression-Free Survival and Evaluate Patient Experience for Patients With Metastatic ALK+ Non-Small Cell Lung Cancer (NSCLC) Treated With ALK InhibitorsStatus: Completed, Estimated PCD: 2023-02-13
Clinical trial
A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2023-02-14
Clinical trial
A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsStatus: Terminated, Estimated PCD: 2022-05-16
Clinical trial
A Phase I/II Open-label Clinical Trial to Evaluate the Pharmacokinetics of Alectinib With Sequential Dose Escalation in Patients Diagnosed With ALK-rearranged Advanced Non-small Cell Lung Cancer.Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Alectinib-induced Endocrine Toxicity in Patients With ALK-positive Advanced NSCLC: an Onservational StudyStatus: Completed, Estimated PCD: 2023-10-30
Clinical trial
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Umbrella Protocol for Phase I/IIa Trials of Molecularly Matched Targeted Therapies Plus Radiotherapy in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation: NCT Neuro Master Match - N²M² (NOA-20)Status: Completed, Estimated PCD: 2023-02-22
Clinical trial
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity - DARWINIIStatus: Active (not recruiting), Estimated PCD: 2026-05-01
Clinical trial
A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLCStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to Determine the Efficacy in Treatment of Advanced Cancers With a Known Molecular ProfileStatus: Recruiting, Estimated PCD: 2026-11-25
Clinical trial
Standard Dosed Alectinib Versus Therapeutic Drug Monitoring Guided Alectinib DosingStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT)Status: Withdrawn, Estimated PCD: 2026-05-31
Clinical trial
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.Status: Recruiting, Estimated PCD: 2026-12-24
Clinical trial
A Pilot Study of Alectinib (Alecensa) in Combination With Nivolumab (Opdivo) in the Treatment of Recurrent or Refractory Hepatocellular Carcinoma Patients Guided With Serum Level of RNase1 and Tumor Expression of PD-L1Status: Recruiting, Estimated PCD: 2024-12-31
Document
DailyMed Label: ALECENSAOrganization
Genentech, Inc.